| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
Total net revenue increased approximately 9% to $19.2 million for the third quarter of 2026 compared to the third quarter of 2025 |
| 01 Oct 2026 |
8-K: Other Events
As previously disclosed, on July 25, 2024, Fortress Biotech, Inc. (the “Company”), as borrower, entered into a $50.0 million senior secured credit agreement (as amended on December 12, 2025 and February 22, 2026, the “Oaktree Agreement”)... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 |
| 23 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2026, Fortress Biotech, Inc. (the “Company” or “Fortress”) held its annual meeting of stockholders (the “2026 Annual Meeting”) at 10:00 a.m. Eastern Time by means of an online virtual meeting platform. |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million |
| 31 Mar 2026 |
8-K: Results of Operations and Financial Condition
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million; Cyprium is also eligible to ... |
| 30 Mar 2026 |
8-K: Other Events
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million |
| 23 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million |
| 13 Jan 2026 |
8-K: Other Events
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States |
| 15 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
On December 12, 2025, Fortress Biotech, Inc. (the “Company”), as borrower, entered into the First Amendment to Credit Agreement (the “Amendment”), which amends that certain Credit Agreement dated July 25, 2024 (the “Agreement”) with Oakt... |
| 15 Dec 2025 |
8-K: Other Events
Miami, FL – December 15, 2025 – Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S. Food and Drug Administration (“FDA”) has accepted... |
| 17 Nov 2025 |
8-K: Other Events
As previously disclosed, on October 1, 2025, Fortress Biotech, Inc. (the “Company”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), announced that the U.S. Food and Drug Administration (the “FDA”) had issued a ... |
| 14 Nov 2025 |
8-K: Results of Operations and Financial Condition
Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 |
| 01 Oct 2025 |
8-K: Other Events
Miami, FL – October 1, 2025 – Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a C... |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition
Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future... |
| 16 Jul 2025 |
8-K: Other Events
As previously disclosed, on October 6, 2021, AstraZeneca’s Alexion Therapeutics, Inc. (“AstraZeneca”) purchased 100% of the equity securities (the “Caelum Acquisition”) of Caelum Biosciences, Inc. (“Caelum”), a privately held biopharmace... |
| 23 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2025, Fortress Biotech, Inc. (the “Company” or “Fortress”) held its annual meeting of stockholders (the “2025 Annual Meeting”) at 10:00 a.m. Eastern Time by means of an online virtual meeting platform. |
| 05 Jun 2025 |
8-K: Completion of Acquisition or Disposition of Assets
As previously disclosed in the Current Report on Form 8-K filed by Fortress Biotech, Inc. (“Fortress” or the “Company”) with the Securities and Exchange Commission (the “SEC)” on March 10, 2025, Checkpoint Therapeutics, Inc., a Delaware ... |
| 15 May 2025 |
8-K: Results of Operations and Financial Condition
Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults |
| 16 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On April 15, 2025, Lucy Lu, M.D., notified Fortress Biotech, Inc. (the “Company”) of her resignation from the Board of Directors effective April 15, 2025. Dr. Lu’s decision to resign from the Board of Directors was made in connection wit... |
Loading...